Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
Madrigal stock catapulted again Friday after Novo Nordisk published not "game-changing" results for its MASH treatment.
Some parts of this page are not supported on your current browser version. Please upgrade to a recent browser version.
Madrigal stock catapulted again Friday after Novo Nordisk published not "game-changing" results for its MASH treatment.